The inventors have demonstrated that incorporating mesenchymal stem cell-derived mitochondria using T-cells induces a significant increase in their anti-inflammatory properties. This innovation could reprogramme T-cells isolated from individuals with inflammatory and/or autoimmune diseases by acquiring specific mitochondria (MT) that induce an anti-inflammatory phenotype. The MT-T-cells obtained could be used as therapeutic agents to effectively reduce inflammation and therefore the symptoms of these diseases.
The present invention relates to a method for the in vitro diagnosis of cardiovascular disease or physiopathological state by detecting, quantifying and characterising biomarkers of membrane proteins linked to extracellular vesicles present in blood plasma. The method provides the quantification of extracellular vesicles containing the hERG1 protein and/or Hsp47 protein.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to a novel internal curing agent based on geopolymers from fly ash, which performs the same or better than the alternatives available on the international market, for use in concrete or mortar mixtures. The advantage of the internal curing agent is that it can be manufactured using local materials with a low large-scale production cost and it can be specifically designed for different applications of concrete construction.
C04B 18/00 - Emploi de matières agglomérées, de résidus ou de déchets comme charges pour mortiers, béton ou pierre artificielleTraitement de matières agglomérées, de résidus ou de déchets, spécialement adapté pour renforcer leurs propriétés de charge, dans les mortiers, le béton ou la pierre artificielle
C04B 18/14 - DéchetsRésidus provenant de procédés métallurgiques
The present invention refers to a pharmaceutical composition comprising a release-controlled nanocarrier consisting of core-shell nanoparticles which in turn comprises EGF growth factor and bFGF growth factor. This pharmaceutical composition in used in the context of the present invention for preventing radiation-induced damage in cancer patients treated with radiotherapy.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61P 39/00 - Agents protecteurs généraux ou antipoisons
5.
DEVICE AND METHOD FOR THE RETRIEVAL OF OSSEOINTEGRATED DENTAL IMPLANTS BY COMBINING THERMAL ENERGY AND ULTRASONIC VIBRATION
A61C 8/00 - Moyens destinés à être fixés à l'os de la mâchoire pour consolider les dents naturelles ou pour y assujettir des prothèses dentairesImplants dentairesOutils pour l'implantation
A61C 3/03 - Instruments fonctionnant par vibration
A61B 18/08 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par chauffage à l'aide de sondes chauffées électriquement
6.
MESENCHYMAL STEM CELLS WITH ENHANCED THERAPEUTIC PROPERTIES
Mesenchymal stem cells with enhanced therapeutic properties. The present invention refers to a method for obtaining mesenchymal stem cells (MSCs) with enhanced immunosuppression, chondroprotection and chondrodifferentiation properties, and enhanced capability to promote the proliferation of chondrocytes. The method comprises contacting the MSCs; culturing MSC in a induction media supplemented with 0.01 to 100 μg/ml of an ATP-synthase inhibitor; and removing the induction media to obtain MSC with enhanced activity. Moreover, the present invention also refers to the MSCs themselves and to their use for cell therapy purposes, preferably for treating autoimmune and/or osteoarticular diseases.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
7.
COMPOSITION COMPRISING A COMBINATION GROWTH FACTORS FOR PREVENTING RADIATION-INDUCED DAMAGE IN CANCER PATIENTS TREATED WITH RADIOTHERAPY
The present invention refers to a pharmaceutical composition comprising a release-controlled nanocarrier consisting of core-shell nanoparticles which in turn comprises EGF growth factor and bFGF growth factor. This pharmaceutical composition in used in the context of the present invention for preventing radiation-induced damage in cancer patients treated with radiotherapy.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present invention refers to the oral and dental health care field since it refers to a modified and improved dental floss material aimed at preventing the onset and progression of dental caries and periodontal disease.
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (France)
UNIVERSITÉ DE MONTPELLIER (France)
Inventeur(s)
Luz Crawford, Patricia
Contreras López, Rafael
Elizondo Vega, Roberto
Djouad, Farida
Abrégé
Mesenchymal stem cells with enhanced therapeutic properties. The present invention refers to a method for obtaining mesenchymal stem cells (MSCs) with enhanced immunosuppression, chondroprotection and chondrodifferentiation properties, and enhanced capability to promote the proliferation of chondrocytes. The method comprises contacting the MSCs; culturing MSC in a induction media supplemented with 0.01 to 100 µg/ml of an ATP-synthase inhibitor; and removing the induction media to obtain MSC with enhanced activity. Moreover, the present invention also refers to the MSCs themselves and to their use for cell therapy purposes, preferably for treating autoimmune and/or osteoarticular diseases.
A61C 8/00 - Moyens destinés à être fixés à l'os de la mâchoire pour consolider les dents naturelles ou pour y assujettir des prothèses dentairesImplants dentairesOutils pour l'implantation
The present invention refers to the oral and dental health care field since it refers to a modified and improved dental floss material aimed at preventing the onset and progression of dental caries and periodontal disease.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (GCF). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the Examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
14.
Gelatin polymer derived from natural sources of cold-adapted marine species and uses thereof
The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
B33Y 70/00 - Matériaux spécialement adaptés à la fabrication additive
15.
BIOMATERIALS COMPRISING GELATIN DERIVED FROM COLD-ADAPTED AQUATIC SPECIES
The present document describes a composition and pharmaceutical composition comprising gelatin derived from a cold-adapted aquatic species, chitosan, agarose and glycerol. Further, the present document discusses a process for manufacturing a biomaterial which comprises gelatin derived from a cold-adapted aquatic species, chitosan, agarose and glycerol. The biomaterial obtained or obtainable through the process is also described. Also, the present document describes a kit which comprises: gelatin derived from a cold-adapted aquatic species, chitosan, agarose, and glycerol. Lastly, the use of the composition, pharmaceutical composition, biomaterial or kit for the production of scaffolds, dressings, beads, engineered tissues, devices or micro-devices suitable for therapeutic or diagnostic purposes or the use of the composition, biomaterial or kit for tissue engineering are also discussed.
A61L 27/26 - Mélanges de matériaux macromoléculaires
A61L 15/22 - Bandages, pansements ou garnitures absorbant les fluides physiologiques tels que l'urine, le sang, p. ex. serviettes hygiéniques, tampons contenant des matériaux macromoléculaires
16.
A FILTERING APPARATUS AND METHOD FOR TREATING POLLUTED AIR IN INDOOR SPACES
The invention relates to a filtering apparatus and method for treating polluted indoor air, which can be operated by gas scrubbers, adsorbers, or through the use of a microbial biodegrading medium for polluting gases, wherein said apparatus allows the biofiltration method to be efficient and applicable in indoor spaces. The technical problem of the efficiency of the filter has to do with said filter being able to process the greatest amount of pollutants during a minimum residence time and with a filter bed volume that allows the application thereof in apparatus that have an adequate size for indoor spaces, such as spaces inside the household, i.e., allowing the reactor to operate at maximum capacity without having to increase the size thereof.
B01D 53/04 - Séparation de gaz ou de vapeursRécupération de vapeurs de solvants volatils dans les gazÉpuration chimique ou biologique des gaz résiduaires, p. ex. gaz d'échappement des moteurs à combustion, fumées, vapeurs, gaz de combustion ou aérosols par adsorption, p. ex. chromatographie préparatoire en phase gazeuse avec adsorbants fixes
F24F 3/16 - Systèmes de conditionnement d'air dans lesquels l'air conditionné primaire est fourni par une ou plusieurs stations centrales aux blocs de distribution situés dans les pièces ou enceintes, blocs dans lesquels il peut subir un traitement secondaireAppareillage spécialement conçu pour de tels systèmes caractérisés par le traitement de l'air autrement que par chauffage et refroidissement par purification, p. ex. par filtrageSystèmes de conditionnement d'air dans lesquels l'air conditionné primaire est fourni par une ou plusieurs stations centrales aux blocs de distribution situés dans les pièces ou enceintes, blocs dans lesquels il peut subir un traitement secondaireAppareillage spécialement conçu pour de tels systèmes caractérisés par le traitement de l'air autrement que par chauffage et refroidissement par stérilisationSystèmes de conditionnement d'air dans lesquels l'air conditionné primaire est fourni par une ou plusieurs stations centrales aux blocs de distribution situés dans les pièces ou enceintes, blocs dans lesquels il peut subir un traitement secondaireAppareillage spécialement conçu pour de tels systèmes caractérisés par le traitement de l'air autrement que par chauffage et refroidissement par ozonisation
B01D 53/18 - Unités d'absorptionDistributeurs de liquides
17.
Automated fabrication of layer-by-layer tissue engineered complex tubes
The present invention overcomes all the above drawbacks and provides a versatile method for the fabrication of multilayer hollow tubes that uses a layer-by-layer rod dipping approach using different biomaterials. The device enables fine control over fabrication parameters, such as ascending/descending speeds, rod rotational velocity, and crosslinking or polymerization time. All these technologies allows the generation of more complex multilayer hollow tubes such as vessel-like structures, urethral grafting, prostate grafting and the like.
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
A61L 27/26 - Mélanges de matériaux macromoléculaires
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
A61L 27/54 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
B32B 9/02 - Produits stratifiés composés essentiellement d'une substance particulière non couverte par les groupes comprenant des substances animales ou végétales
The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (GCF). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the Examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
19.
COMPOSITION COMPRISING A SUBSTANTIALLY PURE POPULATION OF MULTIPOTENT STROMAL CELLS ENCAPSULATED IN PLATELET-POOR PLASMA (PPP)
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
A61K 35/51 - Cordon ombilicalSang de cordon ombilicalCellules souches ombilicales
A61P 1/02 - Préparations stomatologiques, p. ex. médicaments pour le traitement des caries, des aphtes, des périodontites
20.
GELATIN POLYMER DERIVED FROM NATURAL SOURCES OF COLD-ADAPTED MARINE SPECIES AND USES THEREOF
The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.
C08H 1/00 - Produits macromoléculaires dérivés des protéines
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
C08J 3/24 - Réticulation, p. ex. vulcanisation, de macromolécules
21.
AUTOMATED FABRICATION OF LAYER-BY-LAYER TISSUE ENGINEERED COMPLEX TUBES
The present invention overcomes all the above drawbacks and provides a versatile method for the fabrication of multilayer hollow tubes that uses a layer-by-layer rod dipping approach using different biomaterials. The device enables fine control over fabrication parameters, such as ascending/descending speeds, rod rotational velocity, and crosslinking or polymerization time. All these technologies allows the generation of more complex multilayer hollow tubes such as vessel-like structures, urethral grafting, prostate grafting and the like.
A61F 2/00 - Filtres implantables dans les vaisseaux sanguinsProthèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corpsAppareils pour les assujettir au corpsDispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p. ex. stents
22.
NEURITE REGENERATION THERAPY BASED ON EXOSOMES DERIVED FROM MENSTRUAL STEM CELLS
The present invention offers an effective alternative method for treating neurological disorders, preferably those induced by a nerve injury or by a neurodegenerative process. The present invention is the first to show that a substantially pure population of exosomes derived from menstrual stem cells (MenSCs) have the capacity to increase the neuritic outgrowth of cortical and sensory neurons. The present invention shows that a substantially pure population of MenSCs-derived exosomes increases the length of the longest neurite and the ramification pattern of cortical neurons. MenSc and bone marrow stem cells (BMSCs) also promote the neuritic growth of neurons from the dorsal route ganglia. Overall, the invention offers a promising alternative method to treat neurological disorders involving the loss of nerve tissues. Since it is principally composed of exosomes produced by the stem cells present in menstrual fluid, the invention provides an ease access and repeated sampling in a non-invasive manner.
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention is focused on an in vitro method for identifying or screening human subjects at risk of suffering from a pregnancy related disease, in particular from gestational diabetes mellitus or preeclampsia, departing from the level of expression or concentration of a series of biomarkers isolated from a minimally-invasive sample such as gingival crevicular fluid (GCF). Moreover, the method of the invention offers high sensitivity and specificity at an early stage of the pregnancy (see the Examples and figures shown below), which means that it is a strong and cost-effective method for the detection of a pregnancy related disease, in particular gestational diabetes mellitus or preeclampsia, at an early stage of the disease thus procuring effective treatment, avoiding significant long-term adverse effects for both mother and baby.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
24.
DEVICES FOR STUDYING CHEMOTAXIS/ADHERENCE IN CELLS WHEREIN GRADIENTS AND CHANNELS ARE FORMED USING HYDROGELS
This invention provides devices capable of assessing the migration response in the presence of a stable encapsulated gradient of a factor or factor combination, and capable of quantifying the adherence response inside micro-channels in the presence of different factors. This invention also provides a platform for the obtained information thanks to the devices, and it allows obtaining already the migration score or the quantification of adhered cells. Additionally, the invention provides a method to quantify the cells migration response and the cells adherence response.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
25.
Method, systems and kit for forensic identification, post mortem interval estimation and cause of death determination by recovery of dental tissue in physiological conditions
The present invention is related to a method for obtaining dental pulp and root cement in the forensic dentistry field, wherein the method comprises the steps of: (a) obtaining a tooth; (b) taking a digital radiography to the tooth; (c) external rehydrating of the tooth; (d) perforating the rehydrated tooth; (e) internal rehydrating of dentin pulp complex (f) obtaining rehydrated root cement; (g) obtaining rehydrated dental pulp content with a low speed rotation tool; and (h) storing, preservation, processing and/or analyses of the rehydrated dental pulp content and rehydrated root cement, and the use of this method and kits thereof for forensic identification, estimation of post mortem interval (early and late) and determination of possible causes of death.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
A61B 5/1178 - Identification des personnes basée sur la morphologie ou l’aspect de leur corps ou de parties de celui-ci utilisant des données dentaires
A01N 1/00 - Conservation de corps humains ou animaux, ou de parties de ceux-ci
G01N 1/08 - Dispositifs pour prélever des échantillons à l'état solide, p. ex. par coupe à l'outil impliquant un outil d'extraction, p. ex. mèche cylindrique creuse ou trépan
G01N 1/36 - Enrobage ou montage analogue d'échantillons
G01N 1/00 - ÉchantillonnagePréparation des éprouvettes pour la recherche
G01N 23/04 - Recherche ou analyse des matériaux par l'utilisation de rayonnement [ondes ou particules], p. ex. rayons X ou neutrons, non couvertes par les groupes , ou en transmettant la radiation à travers le matériau et formant des images des matériaux
The invention relates to a liquid water flow probe having multiple hot wires, which enables the measurement of speed on land, the liquid water content (LWC) and the liquid water flow (LWF) in fog or mist. The probe includes at least two heated wires suspended on electrically conductive contact pins maintained at constant temperature or compensation of constant temperature relative to the room temperature, wherein the wire sensors are welded to said contact pins or are mechanically retained between slots in the ends of the contact pins and the contact pins have beveled ends and angled upward to prevent the water that impacts the contact pin to pass through to the wire probe.
G01N 25/56 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la teneur en eau
G01N 25/60 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la teneur en eau en mesurant les changements de propriétés du matériau, produits par la chaleur, le froid ou la détente pour déterminer l'humidité de la vapeur
G01N 25/66 - Recherche ou analyse des matériaux par l'utilisation de moyens thermiques en recherchant la teneur en eau en recherchant le point de rosée
G01N 27/14 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la résistance d'un corps chauffé électriquement dépendant de variations de température
27.
FORENSIC IDENTIFICATION, POST MORTEM INTERVAL ESTIMATION AND CAUSE OF DEATH DETERMINATION BY RECOVERY OF DENTAL TISSUE
The present invention is related to a method for obtaining dental pulp and root cement in the forensic dentistry field, wherein the method comprises the steps of: (a) obtaining a tooth; (b) taking a digital radiography to the tooth; (c) external rehydrating of the tooth; (d) perforating the rehydrated tooth; (e) internal rehydrating of dentin pulp complex (f) obtaining rehydrated root cement; (g) obtaining rehydrated dental pulp content with a low speed rotation tool; and (h) storing, preservation, processing and/or analyses of the rehydrated dental pulp content and rehydrated root cement, and the use of this method and kits thereof for forensic identification, estimation of post mortem interval (early and late) and determination of possible causes of death.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
28.
STATINS FOR PERIODONTAL DISEASE AND BONE REGENERATION
The present invention discloses topical compositions comprising at least one statin as the main active compound for primary prevention or treatment of periodontal disease, for complementing standard treatment of periodontal disease, and for bone regeneration. The topical compositions are formulated for example, but not limited to, as toothpaste, mouthwash, tablets to dissolve in the mouth, elements or devices for intraoral slow-release of statins, dental floss, gel for being applied in dental trays, concentrated gel for irrigation of periodontal pockets, fluid (for example in blisters), powder, powder or liquid for preparing a solution, and gel. The present invention also discloses method for primary prevention or treatment of periodontal disease, for complementing standard treatment of periodontal disease, and for bone regeneration, comprising administering the topical compositions in the different formulations to a subject in need thereof.
The present invention relates to a method for monitoring, diagnosis and/or prognosis of hypoxia related disorders using NFAT5, the method comprising the steps of a) providing a body sample; b) concentrating the transcription factors present in the sample; c) detecting and/or quantifying NFAT5 in the treated sample. The invention further comprises a diagnostic kit for determining the presence and/or level of NFAT5, for simple determination of the onset of an hypoxia related disorder or condition in a subject, the kit comprising means for concentrating the transcription factors present in the sample and means for detecting NFAT5.
The present invention relates to a method and a kit for monitoring, diagnosis, prognosis of acute kidney injury in early stage and determination of treatment in subjects suffering thereof. The method comprises the steps of a) providing a urine sample; b) enriching the urine sample in exosomes present in the urine sample using at least one step of immunopurification; c) detecting an acute kidney injury (AKI) marker in the exosome.
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
A61K 38/00 - Préparations médicinales contenant des peptides
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions
brevets
